Trial reportAnticancer research2009
Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.
Trial report in Anticancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors.Infectious agents and cancer · 2024Article
- The interplay of cytokine signaling and non-coding RNAs in head and neck squamous cell carcinoma pathobiology.Molecular biology reports · 2022Review
- Review
- Long noncoding RNA,American journal of translational research · 2020Article
- Constitutive activation and overexpression of NF-κB/c-Rel in conjunction with p50 contribute to aggressive tongue tumorigenesis.Oncotarget · 2018Article
- Hypoxia-inducible factor-1α activation in HPV-positive head and neck squamous cell carcinoma cell lines.Oncotarget · 2017Article
- Effect of HPV on tumor expression levels of the most commonly used markers in HNSCC.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Salivary and serum IL-10, TNF-α, TGF-β, VEGF levels in oropharyngeal squamous cell carcinoma and correlation with HPV and EBV infections.Infectious agents and cancer · 2016Article
- Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer.Scientific reports · 2015Article
- Analysis of Human Papilloma Virus 16/18 DNA and its Correlation with p16 Expression in Oral Cavity Squamous Cell Carcinoma in North-Eastern India: A Chromogenic in-situ Hybridization Based Study.Journal of clinical and diagnostic research : JCDR · 2015Article
- Hybrid Capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers.Applied immunohistochemistry & molecular morphology : AIMM · 2015Article
- Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Head and neck pathology · 2013Article
- Human papilloma virus infection in head and neck cancer.Deutsches Arzteblatt international · 2013Review
- Article
- Frequency and genotype of human papillomavirus among Sudanese patients with head and neck tumours.Ecancermedicalscience · 2012Article
- Article
- The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview.Infectious agents and cancer · 2011Article
- Article
- Human papillomavirus-related disease in men: not just a women's issue.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2010Review
- Recent advances in managing human papillomavirus-positive oropharyngeal tumors.F1000 medicine reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledThe aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1alpha and VEGF expression in HPV-positive and -negative tumors. PATIENTS AND
methodsPatients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx. HPV status was determined by conventional PCR in fresh frozen biopsy samples and by Taqman PCR assay on formalin-fixed, paraffin-embedded specimens. HIF-1alpha and VEGF expression were assessed by quantitative real-time PCR (RT-PCR). Multivariate Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) based on HPV status.
resultsHPV-16 was detected in 14 of 24 evaluable cases. There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively. There was a trend toward better progression-free (HR=0.15, 95% CI=0.002-12.54; p=0.06) and overall survival (HR=0.14, 95% CI=0.001-14.12; p=0.10) for HPV-positive patients. In a subset of 13 fresh frozen samples, RT-PCR revealed a significant increase in VEGF mRNA levels in HPV-positive tumors (p<0.01). No difference was seen for HIF-1alpha expression.
conclusionHPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial. The level of VEGF mRNA was up-regulated in HPV-16-positive tumors possibly through an HIF-1 independent manner.
Indexed as
Identifiers
19443352PMC3582681W1894914911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.